Nike Vapormax Clot On Feet
spread and to those with HER2 positive early breast cancer. It's given after primary treatments for breast cancer, such as surgery, chemotherapy and radiation.
However, heart problems have been linked with the drug's use, including congestive heart failure and a decrease in how well the heart can pump blood out of its main pumping chamber, the left ventricle.
from the United States, Belgium and other countries followed more than 5,000 women with early stage breast cancer for an average of eight years. They were evaluating how often cardiac problems occurred and, when they did, whether they disappeared after the women had taken the drug for the recommended time period.
"There's no question this is a really important drug," Mortimer said, as previous studies have shown trastuzumab to improve survival from this more aggressive form of breast cancer.
"The overall message here is one of tremendous reassurance," said study researcher Dr.
After stopping the drug, the blood pumping problems resolved in more than 87 percent of the two year group and more than 81 percent of the one year group.
The study was published June 9 in the Journal of Clinical Oncology online. Roche, the maker of Herceptin, provided research funding.
Herceptin is used in breast cancers that test positive for HER 2 (human epidermal growth factor receptor 2), which promotes the growth of cancer cells. Herceptin kills the cells, and is known to boost survival, both in those with breast cancer that has Nike Air Vapormax Mesh - Men Shoes
The new study reaffirms that the heart problems linked with the drug don't increase with time, she said, "and that's what is important."
Three cardiac deaths occurred in the two year group, none occurred in the one year treatment group, and two deaths occurred in the no drug group, according to the study.
Congestive heart failure occurred in less than 1 percent of both drug groups. "What this confirms is a very low incidence of cardiac events, even when you give two years of the drug, which is no longer practiced," Nike Air Vapormax Flyknit Red
Leyland Jones and other researchers Nike Vapormax Flyknit Heritage
The new findings reaffirm previous research with shorter follow up times, said Dr. Joanne Mortimer, director of Women's Cancer Programs and co director of the Breast Cancer Program at City of Hope Cancer Center in Duarte, Calif. She reviewed the findings but was not involved in the study.
The researchers followed three groups, each with about 1,700 women. One group did not get trastuzumab. The second group took it for one year and the third for two years. The current standard of care is one year, according to Leyland Jones.
Nearly 10 percent of women in the two year group, and about 5 percent of those in the one year group, had to discontinue the drug due to adverse cardiac problems, such as congestive heart failure, a decrease in the heart's blood pumping ability or other issues.
MONDAY, June Nike Vapormax Clot On Feet 9, 2014 (HealthDay News) As many as one in 10 women taking the breast cancer drug trastuzumab (Herceptin) will experience some type of heart problem, according to new research.
Leyland Jones said.
Blood pumping problems occurred in about 7 percent of the two year group and 4 percent of the one year group. Using the drug may take away those heart protective effects.
Breast Cancer Drug Herceptin Linked to Risk of Heart Problems
The good news from this study is that these problems typically reverse once treatment is finished.
Nike Vapormax Clot On Feet
Nike Vapormax Images